AbCellera Biologics Inc.
ABCL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.37 | -0.15 | 0.22 |
| FCF Yield | -4.09% | -4.47% | -3.34% | -2.73% |
| EV / EBITDA | -24.52 | -27.64 | -14.45 | -23.00 |
| Quality | ||||
| ROIC | -10.70% | -3.54% | -7.08% | -4.11% |
| Gross Margin | 0.00% | 58.68% | -903.45% | -175.27% |
| Cash Conversion Ratio | 0.92 | 0.93 | 0.25 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | -11.17% | -39.05% | -49.65% | -60.98% |
| Free Cash Flow Growth | -34.42% | -106.26% | 6.09% | 50.15% |
| Safety | ||||
| Net Debt / EBITDA | -0.85 | -1.28 | 2.31 | 2.70 |
| Interest Coverage | 0.00 | 0.00 | -13.06 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 416.64 | 399.44 | 2,621.26 | 1,419.53 |